Form 4: Kairos Pharma Director Boosts Equity Holdings

Kairos Pharma Director Hansoo Michael Keyoung received grants of 29,084 Restricted Stock Units under the company's equity incentive plan.

Summary

• Director Hansoo Michael Keyoung of Kairos Pharma, LTD. (KAPA) reported two grants of Restricted Stock Units (RSUs).
• On September 16, 2025, 10,000 RSUs were acquired, originating from a September 16, 2024 grant tied to the company's initial public offering (IPO), vesting in equal installments on the IPO anniversary.
• On October 8, 2025, an additional 19,084 RSUs were acquired, scheduled to vest in full on the first anniversary of the grant date.
• These transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading schedule.
• Following these transactions, Keyoung beneficially owns 3,334 shares of common stock and 25,750 RSUs which remain subject to vesting.

Sentiment

Score: 7

Explanation: The filing reports routine equity grants to a director, which is a positive for aligning management interests with shareholders. There are no negative surprises, but also no immediate catalysts for significant stock movement beyond the general positive sentiment of insider ownership.

Positives

• Director Keyoung's increased equity ownership aligns his interests with those of the company's shareholders.
• The grants are part of the company's 2023 Equity Incentive Plan, indicating a structured and ongoing approach to executive and director compensation.

Risks

• The value of the granted RSUs is directly tied to the future performance of Kairos Pharma's stock, exposing the director to market fluctuations.
• Vesting conditions mean the director does not immediately own all shares, creating a retention incentive but also a potential forfeiture risk if conditions are not met or employment ceases.

Future Outlook

The grants of Restricted Stock Units (RSUs) are designed to incentivize long-term performance and retention of key personnel, aligning their future interests with shareholder value creation. The specified vesting schedules indicate a forward-looking compensation structure aimed at fostering sustained commitment.

Industry Context

Equity grants, particularly Restricted Stock Units (RSUs), are a common and widely accepted form of executive and director compensation in the biotechnology and pharmaceutical industries. These awards are strategically utilized to attract, retain, and motivate top talent by directly linking their compensation to the company's long-term performance and stock appreciation. The use of a Rule 10b5-1 plan is standard practice for insiders to manage their stock transactions in compliance with insider trading regulations, reflecting a commitment to transparent and ethical governance.

Comparison to Industry Standards

• The utilization of Restricted Stock Units (RSUs) as a compensation tool for directors is a standard practice across the biotech and pharmaceutical industries, comparable to leading companies such as Moderna, Pfizer, or Amgen, which frequently employ equity awards to align executive and director incentives with long-term shareholder value.
• The specified vesting schedules, particularly those tied to IPO anniversaries or a single anniversary date, are typical for such grants, aiming to retain talent over several years and ensure sustained commitment.
• The implementation of a Rule 10b5-1 plan for these transactions is a common corporate governance practice, ensuring compliance with insider trading regulations and providing an affirmative defense against potential claims of insider trading.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of Director Keyoung's financial interests with those of shareholders due to his increased equity ownership.
• Employees: May signal a stable and competitive compensation strategy for key personnel, potentially boosting morale and retention efforts.

Next Steps

• Future vesting events for the granted RSUs will occur on the IPO anniversary for the 10,000 RSUs and on the first anniversary of the grant date for the 19,084 RSUs.
• Subsequent Form 4 filings will report any further changes in beneficial ownership by Director Keyoung.

Key Dates

Recommendation

This Form 4 filing reports routine equity grants to a director, which is a standard compensation practice and generally viewed as a neutral to slightly positive event as it aligns insider interests with shareholders. It does not contain information that would fundamentally alter the investment thesis or warrant a change in an existing position. Therefore, a 'hold' recommendation is appropriate, pending further operational or financial news.

Keywords

Kairos Pharma, KAPA, Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Incentive Plan, Director Compensation, Hansoo Michael Keyoung, Beneficial Ownership